Single center analysis of immunotherapy in mCRC patients.
Reinhard Ruckser(Donauspital), Christian Sebesta(Donauspital), Veronika Buxhofer‐Ausch(Johannes Kepler University of Linz), Selma Hoenigschnabl, Elvira Kitzweger, P Zelenka(Universität für Weiterbildung Krems), Georg Tatzreiter(Universität für Weiterbildung Krems), Angelika Reiner‐Concin(Donauspital), P Kier(Universität für Weiterbildung Krems), K H Habertheuer
Cited by 0
Related Papers
Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study
|Journal of Clinical Oncology|2011|540
Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients
|Blood|2011|448
Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study
|The Lancet Haematology|2020|351
Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia
|Blood Cancer Journal|2015|273